Eczema (Atopic Dermatitis) Clinical Trials in Birmingham

View 42 new treatments for Eczema (Atopic Dermatitis) in Birmingham, AL. Every day, Power helps hundreds of Eczema (Atopic Dermatitis) patients connect with leading medical research.
View 31 trials in Birmingham
Filter (31)

Bodewell Calming Cream for Eczema

Research Clinic, Birmingham + 1 more

This trial is testing Bodewell creams or lotions on people with eczema. The products are applied to the skin to help reduce itching and inflammation.
Recruiting

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Tiffany Mayo, MD
Principal Investigator

Abrocitinib for Eczema

Research Clinic, Birmingham + 1 more

This trial tests abrocitinib, a medication taken regularly, on people with atopic dermatitis who didn't respond well to another treatment or have facial redness. It works by reducing inflammation. Abrocitinib is approved in Europe, the United States, and other countries for the treatment of atopic dermatitis in adults whose disease is not controlled with other treatments.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 3 - 6 Weeks
Robert Bissonnette, MD
Principal Investigator

Dupilumab for Eczema

Regeneron Clinic, Birmingham + 3 more

This trial is testing a medication for treating eczema in people with skin of color. Eczema causes itchy, dry, and cracked skin. The medication aims to reduce these symptoms by calming the immune system. The study will also look at side effects, how much of the drug is in the blood at different times, and improvements in quality of life and mental health.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Clinical Trial Management
Study Director

Nemolizumab for Eczema

Galderma Clinic, Birmingham + 2 more

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Waitlist

No Placebo Trial

Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team

Lebrikizumab for Eczema

Eli Lilly Clinic, Birmingham + 1 more

This trial will test the safety and effectiveness of lebrikizumab in people with severe eczema who have already tried another treatment called Dupilumab. Lebrikizumab aims to reduce skin inflammation by blocking a protein that causes it.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Upadacitinib + Topical Corticosteroids for Eczema

AbbVie Clinic, Birmingham + 3 more

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
ABBVIE INC.
Study Director

Rocatinlimab for Eczema

Amgen Clinic, Birmingham + 2 more

This trial is testing a new medication called rocatinlimab to see if it works well and is safe when used alone. It targets patients who might benefit from a new treatment option.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
MD
Study Director

Tralokinumab for Atopic Hand Eczema

LEO Clinic, Birmingham + 1 more

The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to 4 weeks. For the first 16 weeks after screening, trial participants will receive either tralokinumab or dummy injections every two weeks. After the first 16 weeks, all trial participants will receive tralokinumab injections every two weeks for 16 weeks. The last part of the trial is a period of 4 weeks after the end of treatment period, where trial participants are off the drug for safety follow-up.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Medical Expert
Study Director

Abrocitinib for Atopic Dermatitis/Eczema

Pfizer Clinic, Birmingham + 6 more

This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Pfizer CT.gov Call Center
Study Director

Lebrikizumab for Eczema

Eli Lilly Clinic, Birmingham + 1 more

This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 4 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Page 1 of 4

Frequently Asked Questions

How much do eczema clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do eczema clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across eczema trials in Birmingham, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for eczema patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Birmingham is research being conducted for eczema?

Prominent hospitals or neighborhoods in Birmingham conducting clinical trials for eczema are not explicitly listed. However, trials are actively being conducted in various locations, with some centers hosting up to 33 trials as of the latest data.

What promising new drugs are being tested?

In Birmingham, eczema research is focusing on treatments like Monoclonal Antibodies and Janus Kinase (JAK) Inhibitors. Notable drugs being studied include Dupilumab, Tralokinumab, and Upadacitinib.